Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions.
Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions.
Drug Discov Today. 2017 Nov 13;:
Authors: Moghimi SM
Abstract
Injection/infusion reactions to nanopharmaceuticals (and particulate drug carriers) are idiosyncratic and well documented. The molecular basis of nanoparticle-mediated injection reactions is debatable, with two hypotheses as front-runners. The first is complement-activation-related 'pseudoallergy', where a causal role for nanoparticle-mediated complement activation in injection/infusion reactions is considered. However, the second hypothesis (the rapid phagocytic response hypothesis) states a transitional link from robust clearance of nanoparticles (NPs) from the blood by strategically placed responsive macrophages to adverse hemodynamic and cardiopulmonary reactions, regardless of complement activation. Here, I critically examine and discuss these hypotheses. Current experimentally derived evidence appears to be more in support of the rapid phagocytic response hypothesis than of the pseudoallergy hypothesis.
PMID: 29146517 [PubMed - as supplied by publisher]
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Moghimi SM Tags: Drug Discov Today Source Type: research